IMPLICATIONS FOR PATIENT CARE: Preclinical data indicate a more favorable tumor-to-kidney uptake for 177Lu-rhPSMA-10.1 than for 177Lu-PSMA-I&T and a greater tumor suppression, suggesting that it is a promising next-generation RPT. The gene discussed is FOLH1; the disease is neoplasm.